Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

e inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward looking statements could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertaint
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... federal government, announced in a paper published this week in the scientific journal ... with the diagnostic techniques currently used to detect the Ebola virus. Noblis worked ...
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... in its Phase 1/2 clinical trial of RCT-01, ... Achilles tendinosis, has been enrolled and their tissue ... injections. RCT-01 is comprised of non-bulbar dermal sheath ...
(Date:6/29/2015)... ... ... This cutting edge standard making is a madatory tool for use in ... is the world’s first cuvette-shaped, solid-state filter that lets metrologists and quality control personnel ... calibration standards, such as those made from didymium glass were only able to operate ...
(Date:6/29/2015)... 29, 2015  AACC, a global scientific and ... laboratory medicine, is pleased to announce that the ... , has increased to 7.9 in the 2014 ... Clinical Chemistry in the top 3% ... influence of the research it publishes on laboratory ...
Breaking Biology Technology:Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... WYE ),today announced that its Board of Directors has ... immediately. Mr. Davidson will,continue in his role as Vice ... divisional financial positions since joining the Company,in 1984. These ... Officer, Wyeth Consumer Healthcare and Deputy Treasurer, Wyeth. ...
... Abercrombie, Pfizer R&D Head Martin,Mackay, HHS Deputy Secretary Tevi ... Agenda at FDA/CMS Summit 2007, WASHINGTON, Nov. 15 ... drug approvals. Unfortunately for the biopharma sector and,investors, it,s ... on track,to grant marketing approval to 18 or fewer ...
... MONICA, Calif., Nov. 15 Aida,Pharmaceuticals, Inc. (OTC Bulletin ... 10Q for the period ended September 30, 2007. Net,revenues ... of,5% over the same period in 2006. Gross profit ... Goods Sold. Most notably, sales from Aida,s,transfusion and injection ...
Cached Biology Technology:So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 2So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market 3Aida Files 10Q 2Aida Files 10Q 3Aida Files 10Q 4
(Date:6/24/2015)... , June 22, 2015 ... announced the addition of the "Huawei Ascend ... report to their offering. Huawei,s ... to the opposite direction than Apple,s and Samsung,s ... fingerprint sensor developed by Fingerprint Cards, a main ...
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... turned off or left on in healthy ... common cancers and maybe help avoid them, Medical College ... alterations, called DNA methylation, in the body,s basic building ... and their cancerous counterpart to find telltale patterns that ...
... A new study finds that most older long-term cancer survivors ... health habits. The study also reveals that those survivors ... health and quality of life. Published in the September 1, ... the American Cancer Society, the research indicates that greater efforts ...
... The results of a national assessment of indoor location ... announced at Worcester Polytechnic Institute (WPI) during the 2009 ... Emergency Responders, which runs from Aug. 3 to 4. ... with funding from the Department of Homeland Security and ...
Cached Biology News:Cancer's distinctive pattern of gene expression could aid early screening and prevention 2Cancer's distinctive pattern of gene expression could aid early screening and prevention 3Cancer's distinctive pattern of gene expression could aid early screening and prevention 4Most older long-term cancer survivors have poor health habits 2Results of national assessment of first responder location systems to be announced Aug. 3 2Results of national assessment of first responder location systems to be announced Aug. 3 3Results of national assessment of first responder location systems to be announced Aug. 3 4
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human SCP3 Affinity Purified Polyclonal Ab Keywords: Spermatogenesis, meiosis Protein Family: Cell Cycle...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Human Rad1 MAb (Clone 33)...
Biology Products: